Clinical trials: Chidamide, open to volunteers
Diffuse Large B-Cell Lymphoma (DLBCL)
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Efficacy and safety of chidamide in combination with the R-mini CHOP regimen, followed by chidamide plus CD20 monoclonal antibody as maintenance therapy, in elderly patients with newly diagnosed MYC/BCL2 double-expressor DLBCL.
- Trial name
- NCT07493148
- Testing
- Chidamide, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ou Bai, MD/PHD
Peripheral T Cells Lymphoma (PTCL)
Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of linperlisib combined with chidamide in the treatment of relapsed or refractory peripheral T-cell lymphoma
- Trial name
- NCT07139353
- Testing
- Linperlisib, Chidamide
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
DLBCL
CR-CHOP+X in Previously Untreated DEL
This is a prospective, single-arm, open-label phase II clinical trial that evaluates the efficacy and safety of CR-CHOP regimen combined with different targeted drugs based on different molecular subtypes in newly diagnosed DEL…
- Trial name
- NCT06701357
- Testing
- CR-CHOP+PD1 inhibitor, CR-CHOP + Orelabrutinib, CR-CHOP + decitabine
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Ruijin Hospital
HIV-1-infection
A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir
To assess the impact of UB-421 and chidamide in changing HIV-1 viral reservoir profile among HIV-1 suppressed patients who undergo short-term ART interruption.
- Trial name
- NCT04985890
- Testing
- UB-421, UB-421+chidamide
- Volunteers
- 20 people
- Sponsor
- UBP Greater China (Shanghai) Co., Ltd
Chidamide, R-CHOP Chemotherapy
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
Evaluation of the Safety and Efficacy of CR-CHOP Treatment in Newly Diagnosed Double-Expressor DLBCL with Other Molecular Subtypes
- Conditions
- Chidamide, R-CHOP Chemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, Double-expressor Lymphoma (DEL)
- Trial name
- NCT06891157
- Testing
- Chidamide plus R-CHOP
- Where
- China
- Volunteers
- 148 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
HR+/HER2- Advanced Breast Cancer, Targeted Therapy
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
To explore the efficacy and safety of chidamide combined with endocrine in phosphoinositide-3-kinase,catalytic,alpha gene(PI3KCA) wild type hormone receptor positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-)…
- Trial name
- NCT05983107
- Testing
- Everolimus, Chidamide, Endocrine therapy
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Leukemia, Myeloid, Acute
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
The goal of this clinical research study is to learn if azacitidine combined with Chidamide will help to control the disease in patients with high-risk AML after an allogeneic stem cell transplant.
- Trial name
- NCT05270200
- Testing
- Azacitidine, Chidamide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhujiang Hospital
Peripheral T-Cell Lymphoma
The Efficacy of CAPCT in Patients With PTCL
This study is a multicenter, single-arm, non-randomized, open-label trial designed to evaluate the efficacy and safety of chidamide and azacitidine in combination with prednisone, cyclophosphamide, and thalidomide (CAPCT regimen)…
- Trial name
- NCT07746245
- Testing
- Chidamide, Azacitidine (AZA), Prednisone
- Where
- China
- Volunteers
- 58 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
This study was designed to compare the efficacy and safety of SHR2554 with Chidamide in patients with relapsed/refractory PTCL.
- Trial name
- NCT06122389
- Testing
- SHR2554; Chidamide analog tablets, SHR2554 analog tablets; Chidamide
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Colorectal Cancer Metastatic
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
The prognosis of most patients with unresectable locally advanced or metastatic colorectal cancer (CRC) remains poor despite the advancements in chemotherapy and target therapy.
- Trial name
- NCT06685276
- Testing
- Fruquintinib, Sintilimab, Chidamide
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Dai, Guanghai
Peripheral T-Cell Lymphoma Refractory
An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.
An Open-Label, Single-Arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy of Azacitidine, Chidamide, and PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-Cell Lymphoma.
- Trial name
- NCT07598578
- Testing
- Azacitidine (AZA)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Colorectal Cancer
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
A randomised, open-label, multicenter phase III study to evaluate the efficacy and safety of tucidinostat in combination with sintilimab and bevacizumab versus fruquintinib monotherapy in MSS/pMMR colorectal cancer patients.
- Trial name
- NCT06497985
- Testing
- Tucidinostat, Sintilimab, Bevacizumab
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Chipscreen Biosciences, Ltd.
PTCL
A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.
The efficacy and safety of chidamide in first-line maintenance therapy for PTCL will be assessed through a retrospective case analysis.
- Trial name
- NCT05967949
- Testing
- chidamide
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Peripheral Blood Stem Cell Transplantation
Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen
The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Chidamide intensified conditioning regimen in patients with Acute B cell Lymphoblast leukemia Underwenting Haploidenticl Peripheral blood Stem…
- Trial name
- NCT05088226
- Testing
- Ruxolitinib combined with Chidamide.
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chinese PLA General Hospital
New Diagnosed Angioimmunoblastic T-Cell Lymphoma
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL
Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive lymphoma. At present, the treatment of new diagnosed AITL has limited efficacy and a high recurrence rate.
- Trial name
- NCT07168317
- Testing
- tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
BTC
Chidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT as Second-Line Treatment for Advanced BTC
This study is a prospective, single-arm, multicenter, exploratory clinical trial. It aims to evaluate the efficacy and safety of chidamide combined with benmelstobart, nab-paclitaxel, and immunogenic radiotherapy (SBRT) as…
- Trial name
- NCT07890506
- Testing
- chidamide+benmelstobart+nab-paclitaxel+SBRT
- Where
- China
- Volunteers
- 41 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Metastatic Pancreatic Cancer
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
This is a single-center, open-label, exploratory study aims to assess the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma.
- Trial name
- NCT06951997
- Testing
- QL1706, Chidamide, Gemcitabine
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
The prognosis for patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who refuse or are ineligible for transplant is poor.
- Trial name
- NCT06393361
- Testing
- Chidamide; Decitabine; Anti-PD-1 Antibody, Brentuximab Vedotin, anti-PD-1 antibody.
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
AML, Acute Myeloid Leukemia
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
To evaluate the feasibility, effectiveness and safety of chidamide combined with venetoclax and azacitidine in the treatment of newly diagnosed acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy.
- Trial name
- NCT06386302
- Testing
- Chidamide, Venetoclax, azacitidine
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
To compare the efficacy and safty of ABC-14 regimen with the traditional "3+7" regimen or AB-14 regimen in the treatment of newly diagnosed acute myeloid leukaemia
- Trial name
- NCT06451861
- Testing
- Chidamide, Venetoclax, azacitidine
- Where
- 13 sites in China
- Volunteers
- 240 people
- Sponsor
- Guangdong Provincial People's Hospital